This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell lymphomas who are treated with carfilzomib, lenalidomide and romidepsin in a 3+3 design. The phase IIa portion of the study will involve a dose expansion at the MTD to better characterize the efficacy and to inform further disease specific studies.